ReviewNature reviews. Clinical oncology2026
Unresectable stage III non-small-cell lung cancer: state of the art and challenges.
Review in Nature reviews. Clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta-Analysis.International journal of cancer · 2026Pooled it
- Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.Frontiers in nutrition · 2026Pooled it
- CONUT score and Naples prognostic score (NPS) for dual prediction of survival and radiation toxicity in locally advanced non-small cell lung cancer with chemoradiotherapy.Journal of thoracic disease · 2026Article
- Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study.Current oncology (Toronto, Ont.) · 2026Observational
- Review
- Chemoimmunotherapy improves surgical resection rate and survival versus chemotherapy in potentially resectable non-small cell lung cancer: a real-world propensity score-matched study.Journal of thoracic disease · 2026Article
- Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
- Role of Cytokines in Oligometastatic Non-Small-Cell Lung Cancer Treated with Stereotactic Radiation Therapy: An Observational Pilot Study.Biomolecules · 2026Observational
- Exploration of immunotherapy modalities in stage III unresectable non-small cell lung cancer (Review).Oncology letters · 2026Review
- Efficacy and safety analysis of induction therapy for unresectable locally advanced non-small-cell lung cancer: a retrospective study based on IPTW.Frontiers in oncology · 2026Article
- Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14).Frontiers in immunology · 2026Article
- Synergistic nanomedicine overcomes hypoxia-driven DNA repair to potentiate radiotherapy for lung adenocarcinoma.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in immunotherapy, unresectable stage III non-small-cell lung cancer (NSCLC) remains a highly challenging disease, with only around one-third of patients remaining disease-free at 5 years. The PACIFIC trial established consolidation with the anti-PD-L1 antibody durvalumab after concurrent chemoradiotherapy as the standard-of-care approach. Furthermore, the LAURA trial has redefined the treatment of patients with stage III unresectable EGFR-mutant NSCLC, demonstrating unprecedented progression-free survival durations with osimertinib consolidation. Despite these advances, novel approaches are urgently needed. Circulating tumour DNA-based monitoring of minimal residual disease is emerging as a personalized method of tailoring treatment duration and escalation strategies. Novel radiotherapy techniques have the potential to provide synergy with immunotherapy while minimizing toxicities. Additionally, ongoing trials evaluating chemoimmunotherapy combinations adapted from the neoadjuvant setting with the potential for conversion to resectable disease might, in the near future, redefine the boundary of surgical resectability. In this Review, we describe the rapidly evolving field of unresectable stage III NSCLC, providing a state-of-the-art overview that includes challenging topics such as biomarkers, personalization of therapy and the role of immunotherapy rechallenge.
Indexed as
Identifiers
41068447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.